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Background 
 
Liver cirrhosis is the pathologic outcome of many chronic liver diseases, in which 
repeated injury to the liver results in fibrosis, scarring, and ultimately functional 
impairment (1). The classic defining histological evaluation of cirrhosis will reveal 
diffuse regenerative nodules surrounded by dense fibrosis, with parenchymal distortion 
and collapse causing disruption in hepatic vascular structures (2). There are many causes 
of cirrhosis, such as viral hepatitis, alcohol related fatty liver disease, non-alcoholic fatty 
liver disease (NAFLD), biliary diseases, Wilson’s disease, alpha1-antitrypsin deficiency, 
and hemochromatosis (1, 3). Cirrhosis is regarded as an end-stage disease that has a high 
mortality, and liver transplantation serves as the only true curative treatment (2).  
However, due to recent advances in treatment and management of patients with chronic 
liver disease, early detection allows for early treatment, which leads to favorable patient 
outcomes (4). Imaging and image-guided procedures have a role in prevention, screening, 
diagnosis, and management of cirrhosis (2).  
   It is important to establish the diagnosis of cirrhosis early in the disease process for a 
variety of reasons. It has been shown that fibrosis even in later stages of disease may 
regress with specific therapy, such as in the case with chronic hepatitis B and chronic 
hepatitis C (2). The challenge is that chronic liver disease is often asymptomatic until the 
patient develops cirrhosis and decompensates with signs of sepsis, ascites, variceal 
hemorrhage, encephalopathy, or non-obstructive jaundice (2).  The gold standard for 
diagnosis of cirrhosis has traditionally been a liver biopsy (3, 4). Currently, minimally 
invasive methods such as radiological imaging (ultrasound, computed tomography, and 
magnetic resonance imaging) and serum markers have become more favorable options in 
diagnosis, staging, and grading of chronic liver diseases (4). Most physicians rely on 
imaging and clues of impaired hepatic function as the major basis for diagnosis of 
cirrhosis. The prognosis is highly variable for cirrhosis with a one-year mortality ranging 
from 1%-57% depending on the stage (2). 
 
 
  
Ultrasound 
 
Ultrasound (US) is commonly the first imaging procedure performed during the 
evaluation of suspected liver disease. The role of ultrasound in cirrhosis includes 
screening for hepatocellular carcinoma (HCC) and diagnosis of cirrhosis, portal 
hypertension, and HCC. Ultrasound is readily available, relatively inexpensive, radiation-
free, and offers real time evaluation of the liver parenchyma, border, vascular 
architecture, and vascular flow (4, 5).  Normal liver parenchyma has a homogenous 
echotexture with marginally higher echogenicity compared to the adjacent kidney (6).  
Normal hepatic vessels have smooth walls with anechoic lumens and low resistance 
waveforms; normal portal veins have thin echogenic walls and monophasic waveforms; 
and normal hepatic veins lack discernible walls and have a triphasic waveform (6).  
   Findings of cirrhosis on US include an irregular and nodular surface, coarse 
echotexture, blunt edges, decreased right lobe–caudate lobe ratio, and indirect evidence 
of portal hypertension (1, 7).  Surface nodularity has been shown to be the most common 
ultrasound feature in detection of cirrhosis (8). The alternating areas of necrosis and 
regenerative nodules result in areas of parenchymal collapse and bulging. Ultrasound 
with linear array transducers can provide high-resolution images of the capsule of the 
liver, picking up even subtle cases of nodularity (9).  Although nodularity is a fairly 
specific sign for cirrhosis, other differential diagnoses include subcapsular metastases, 
peritoneal seeding, or pseudomyxoma peritonei, which can all mimic cirrhosis (9). 
Ultrasound can detect cirrhosis with an accuracy of 64-79%, sensitivity of 52-69%, and 
specificity of 74-89% (1).   The ability to additionally evaluate for other signs and 
complications of cirrhosis, such as dilated portal vein/portosystemic collaterals, 
splenomegaly and ascites indicating portal hypertension, makes ultrasound an even 
stronger method for evaluation (6).  
   Color Doppler, a modality used in US, can show portal vein flow, flow reversal, and 
collateral flow, which help evaluate for portal hypertension. It has been noted that 
reversal of flow (hepatofugal flow) and/or collateral flow may be the only findings of 
cirrhosis in otherwise asymptomatic patients, showing the importance of color doppler in 
the evaluation of cirrhosis (5).  Other findings on color Doppler include enlarged, 
tortuous hepatic arteries (corkscrew appearance) suggesting increased flow velocity (5).  
There may also be stasis in the hepatic veins as in the case of thrombosis (6). As cirrhosis 
progresses, the normal triphasic waveform of the hepatic veins become biphasic and even 
monophasic because of diminished vascular compliance secondary to fibrosis (6).  
Because cirrhosis is the most common cause of portal hypertension, the findings of 
portosystemic collaterals or flow reversal should prompt and support evaluation of the 
diagnosis of cirrhosis (5). The limitations of ultrasound include operator dependence, and 
difficulty visualizing the entire liver. The main advantage of ultrasound is that it has a 
high negative predictive value for cirrhosis (8). 
   Sonographic elastography is a noninvasive and innovative method assessing liver 
fibrosis, and thus cirrhosis. There are three techniques available: transient elastography 
(Fibroscan), acoustic radiation force impulse elastography (ARFI), and ShearWave 
elastography (SWE) (1, 10).  For moderate fibrosis (fibrosis stages 1 and 2), the 
technique of choice is Fibroscan as it produces significantly better results than ARFI 
elastography (1). The limitations of Fibroscan include missed diagnoses in 2-11% of 
cases, the operator-dependent nature of the test, difficult measurement in obese patients 
and ascitic patients and the small volume of liver parenchyma that is measured (1). A 
meta-analysis by Talwalker et al. showed that for patients with stage IV fibrosis (or 
cirrhosis), with regards to ultrasound transient elastography (Fibroscan), the pooled 
sensitivity was 87% and specificity was 91%, and among stage II-IV fibrosis the 
sensitivity was 70% and specificity was 84% for detection of cirrhosis (11). 
 
Computed tomography 
 
Abdominal computed tomography (CT) is a frequently used study obtained because of its 
wide range of utility. As a part of routine evaluation of the CT images, the liver is 
screened for fibrosis and parenchymal changes.  Findings of cirrhosis on CT include an 
irregular/nodular surface, blunt liver edge, parenchymal and morphological changes, and 
signs of portal hypertension. The diagnostic accuracy, sensitivity, and specificity have 
been shown to be 67–86%, 77–84% and 53–68% (1, 7). Using a cirrhosis scoring criteria 
developed by Harbin et al., with the ratio of transverse caudate lobe width to transverse 
right lobe width, cirrhotic livers could be separated from non-cirrhotic livers with an 
accuracy, sensitivity, and specificity of 94%, 84%, and 100% (12).  Limitations of 
diagnostic CT include cost and radiation exposure, making the radiation free and 
inexpensive ultrasound more appealing as an initial test. The advantage of CT imaging 
over ultrasound is its ability to detect HCC and perform staging post contrast injection 
(1). The best predictive signs of liver cirrhosis on CT and MRI were liver parenchymal 
abnormalities, manifestation of portal hypertension, and morphological changes (7). In a 
multicenter study review by Kudo et al., MRI and CT were deemed superior in sensitivity 
to US in predicting cirrhosis since they evaluate the hepatic parenchyma and morphology 
better than ultrasound (7). 
 
Magnetic resonance imaging 
 
Magnetic resonance imaging (MRI) is another modality that can detect features of 
cirrhosis, including surface irregularity, heterogenous enhancement, caudate lobe 
enlargement, splenomegaly, decreased right to left lobe volume ratio, varices, expanding 
gallbladder fossa, and ascites (1). The sensitivity and specificity of contrast enhanced 
MRI for cirrhosis is similar to that of CT.  However, by measuring the diameter of 
hepatic veins, particularly for a right hepatic vein <7mm, Zhang et al. shows an increase 
in detecting cirrhosis with a sensitivity and specificity of 88% and 85% (13).   
   Through the use of MR elastography, double contrast enhanced MRI, diffusion-
weighted MRI, susceptibility-weighted MRI, and T1rho, the detection of liver fibrosis in 
pre-cirrhotic stage was detected with great accuracy.  MR elastography (MRE) may be 
the most reliable of these newer MRI based methods, as it appears to be more accurate 
for detecting fibrosis early and measuring the stiffness of the liver as a whole, with a 
sensitivity and specificity of 98% and 99% (14). Some argue this newer technique may 
even replace the gold standard biopsy as it allows for evaluation of the entire hepatic 
volume in an accurate manner. The limitations of MRE are the cost and limitations in 
patients with hepatitis and congestive heart failure (14). The imaging modalities 
described above are summarized in table 1. 
  
 
 
 
Table 1. Imaging modalities in detection of cirrhosis 
 Ultrasound CT MRI 
Findings of cirrhosis  Surface 
irregularity 
 Coarse 
echotexture 
 Decreased R lobe 
– caudate lobe 
ratio 
 Evidence of 
portal 
hypertension 
 Surface 
irregularity 
 Parenchymal 
changes 
 Signs of portal 
hypertension 
  
 Surface 
irregularity 
 Heterogenous 
enhancement 
 Caudate lobe 
enlargement 
 Decreased R to 
L lobe volume 
ratio 
 Expanding 
gallbladder 
fossa 
 Varices and 
Ascites 
Sensitivity/Specificity 
 
52-69% / 74-89% 77-84% / 53-68% 88% / 85% 
Role in cirrhosis and 
HCC 
 Screening and 
surveillance  
 Diagnosis   Diagnosis  
Pros  No radiation 
exposure 
 Low cost and 
availability 
 Color doppler 
assessment of 
flow 
 Sonographic 
elastography 
assessment of 
fibrosis 
 Highest 
specificity 
 Higher 
sensitivity 
than US 
 Visualization 
of entire liver 
 
 No radiation 
exposure 
 Most sensitive 
in detection of 
cirrhosis 
 Good 
specificity 
 Visualize entire 
liver 
 Detection of 
small HCC 
Cons  Not as sensitive 
as CT/MRI 
 Operator 
dependent 
 Unable to 
visualize entire 
liver 
 Radiation 
exposure 
 Cost is higher 
than US 
 Cost is higher 
than US and CT 
 More time 
intensive 
Screening for HCC 
 
The late presentation of chronic liver disease emphasizes the importance for population 
screening, especially in high-risk patients. Currently, screening for chronic hepatitis C is 
an accepted screening method for patients born between 1945-1965. Other screening 
methods include NAFLD fibrosis scores for non-alcoholic fatty liver disease and alcohol 
misuse screening (2).  Once diagnosed with cirrhosis, The American Association for the 
Study of Liver Diseases (AASLD) recommends that patients should be evaluated for 
esophageal and gastric varices with a screening esophagogastroduodenoscopy (EGD) and 
treated accordingly to the findings (15, 16).  
   Hepatocellular carcinoma accounts for a large majority of all primary liver cancers, 
with the highest incidence rates in regions with high hepatitis B virus and hepatitis C 
virus infection (17).  Aside from HBV and HCV, other risk factors for HCC include 
alcoholic liver disease, nonalcoholic fatty liver disease, and in general, diseases leading 
to cirrhosis (17).  
   In patients with cirrhosis, HCC has been shown to develop at a rate of 1%-4% per year 
(18). The American Association for the Study of Liver Diseases (AASLD) has developed 
a system for surveillance based on the level of risk of HCC (19). For high-risk patients, 
AASLD recommends ultrasound screening at diagnosis and every six months (19). The 
screening interval does not need to be shortened for patients at higher risk of HCC (19).  
The AASLD recommends that HCC surveillance is deemed cost effective if the risk of 
HCC exceeds 1.5% per year in patients with hepatitis C and 0.2% per year in patients 
with hepatitis B.  They also recommend that alpha-fetoprotein alone lacks the necessary 
sensitivity and specificity to be effective for surveillance and diagnosis, and although 
AFP with ultrasound increases detection rates, it also increases false positives and cost 
(19). In conclusion, ultrasound every six months is the best modality for surveillance. 
   In the event that a nodule larger than 1 cm is found on ultrasound screening, the 
AASLD recommends evaluation with dynamic contrast enhanced MRI or 4-phase 
multidetector CT (17).  If the nodule is smaller than one centimeter, then the patient 
should have a follow up ultrasound at 3-6 month interval (19). After two years of 
documented no growth, the patient may return to routine surveillance with a screening 
ultrasound every six months (19). The AASLD guidelines on surveillance of HCC are 
summarized in table 2.  
  
 Table 2. Summary of AASLD guidelines on surveillance of HCC 
High risk patients Recommendations 
-Hepatitis B 
 Asian male hepatitis B carrier with 
age >40 
 Asian female hepatitis B carrier 
with age >50 
 Hepatitis B carrier with family 
history of HCC 
 African/North American Blacks 
with hepatitis B 
 Chronic Hepatitis B carriers 
-Hepatitis C cirrhosis 
-Stage 4 primary biliary cirrhosis 
-Genetic hemochromatosis and cirrhosis 
-Alpha 1-Antitriypsin deficiency and 
cirrhosis 
-Other cirrhosis 
1. Patients should be entered into 
surveillance programs 
2. Surveillance should include 
ultrasound at six month intervals 
-Patients on the transplant waiting list 1. Screen for HCC as it affects priority 
for OLT 
For additional details, refer to:  
Bruix, J., & Sherman, M. (2011). Management of hepatocellular carcinoma: an 
update. Hepatology, 53(3), 1020-1022 
 
 
 
Conclusion 
 
Cirrhosis is an increasing cause of morbidity and mortality that requires accurate and 
early detection for optimal treatment and management. Ultrasound is commonly the first 
step in radiological examination in patients suspected of having liver disease. The 
ultrasound findings in conjunction with using color Doppler to assess for flow velocities 
allows for better detection of cirrhosis, portal hypertension, and hepatocellular 
carcinoma. However, nonspecific findings should be further evaluated by CT, MRI, or 
biopsy depending on the clinical context. Hepatocellular carcinoma accounts for the 
majority of all primary liver cancers, and develops at an increased rate in patients with 
cirrhosis. Due to this increased risk, the AASLD has developed guidelines for 
surveillance and management of patients at risk for HCC. 
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